Protein Kinase Inhibitors: all 15,278 studies that test it

Page 105 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Carbon Ion Radiation Therapy for Locally Advanced Pancreatic CancerCompletedNCT03403049Phase 1
• A Study to Investigate BMS-986165 and Methotrexate in Healthy Male PatientsCompletedNCT03402087Phase 1
• Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")WithdrawnNCT03400254Phase 1/2
• The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR MutationStatus unknownNCT03399669Phase 2
• Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell LymphomaCompletedNCT03399513Phase 2
• A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementStatus unknownNCT03399487Phase 2
• Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal CancerStatus unknownNCT03397199Phase 2
• A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerCompletedNCT03396211Phase 1
• Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerStatus unknownNCT03396185Phase 2
• Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedNCT03395899Phase 2
• TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid BiopsyCompletedNCT03394118Phase 2
• A Study of Apatinib Treatment in for Advanced Ovarian CancerStatus unknownNCT03393507Phase 2
• A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03392246Phase 2
• A Study of Apatinib in Recurrent or Recurrent High-grade GliomaStatus unknownNCT03390062Phase 2
• A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor PatientsStatus unknownNCT03389815Phase 1/2
• Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLCStatus unknownNCT03389256Phase 2
• Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung CancerStatus unknownNCT03389087Phase 2
• Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaStatus unknownNCT03387904Phase 2
• BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung CancerCompletedNCT03386955Phase 1/2
• A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and MoxifloxacinCompletedNCT03386279Phase 1
• Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With MyelofibrosisTerminatedNCT03386214Phase 1
• SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast CancerTerminatedNCT03386162Phase 2
• Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2
• The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.CompletedNCT03384511Phase 4
• Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ SyndromeCompletedNCT03383380Phase 1/2
• Clinical Study of Apatinib as the Second-line Therapy in Malignant MelanomaStatus unknownNCT03383237Phase 2
• A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.Status unknownNCT03381066Phase 3
• Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal CancerStatus unknownNCT03377842Phase 2
• Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast CancerCompletedNCT03377387Phase 1/2
• A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaCompletedNCT03377179Phase 2
• Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerWithdrawnNCT03377101Phase 2
• Apatinib for Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT03376958Phase 4
• Study of Apatinib as the Maintenance Therapy in Advanced Lung AdenocarcinomaStatus unknownNCT03376737Phase 2
• Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyActive, not recruitingNCT03373903Phase 2
• Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisTerminatedNCT03373877Phase 1
• Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
• Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-VarlitinibCompletedNCT03368846Phase 1
• AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]TerminatedNCT03366675Phase 2
• A Pilot-Study of Sirolimus for the Treatment of Systemic SclerosisStatus unknownNCT03365869Phase 2
• mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal CancerCompletedNCT03365765Phase 3
• Sirolimus Treatment for Refractory PRCACompletedNCT03364764Phase 4
• BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
• A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult SubjectsCompletedNCT03363815Phase 1
• Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.Active, not recruitingNCT03363217Phase 2
• Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaWithdrawnNCT03361319Phase 1/2
• Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759CompletedNCT03360929Phase 1/2
• A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorWithdrawnNCT03359733Phase 1
• Rapamycin Treatment for ALSCompletedNCT03359538Phase 2
• Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT03359460Phase 1
• A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedNCT03357627Phase 1
• Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung CancerStatus unknownNCT03356600Phase 2
• A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based TherapyStatus unknownNCT03356587Phase 2
• Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6CompletedNCT03356223Phase 2
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)CompletedNCT03355794Phase 1
• A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).CompletedNCT03355157Phase 4
• caBozantinib in cOllectiNg ductS Renal Cell cArcInomaCompletedNCT03354884Phase 2
• Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic MelanomaCompletedNCT03352947Phase 2
• A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal JunctionStatus unknownNCT03349866Phase 2
• HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric CancerTerminatedNCT03349827Not applicable
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
• Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerStatus unknownNCT03349203Phase 2
• Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast CancerStatus unknownNCT03348098Phase 2
• Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1
• Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung CancerStatus unknownNCT03346811Phase 2
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433Active, not recruitingNCT03345823Phase 3
• Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT03343600Phase 2
• A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedNCT03341884Phase 1
• Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCStatus unknownNCT03341845Phase 2
• Multiorgan Metabolic Imaging Response Assessment of AbemaciclibCompletedNCT03339843Phase 2
• A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesWithdrawnNCT03338881Phase 1
• Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric CancerStatus unknownNCT03334591Phase 2
• Efficacy and Safety of Nilotinib in CML-CPCompletedNCT03332511Phase 4
• Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer PatientsCompletedNCT03330990Phase 1
• Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic MalignanciesCompletedNCT03328494Phase 1
• A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT03328273Phase 1
• A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung InjuryCompletedNCT03328117Phase 1
• Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
• Intermittent Dosing Of Selumetinib In Childhood NF1 Associated TumoursCompletedNCT03326388Phase 1/2
• Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.TerminatedNCT03325296Phase 2
• Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)CompletedNCT03324373Phase 1
• A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid LeukemiaWithdrawnNCT03324243Phase 2
• Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell CarcinomaWithdrawnNCT03323710Phase 2
• HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceTerminatedNCT03322215Phase 2
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.TerminatedNCT03320876Phase 2
• GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
• A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCCTerminatedNCT03318562Phase 2
• Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by SurgeryCompletedNCT03317119Phase 1
• Bioavailability Study of K0706 in Healthy SubjectsCompletedNCT03316820Phase 1
• Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy VolunteersCompletedNCT03315494Phase 1
• A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)CompletedNCT03314922Phase 1
• Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal MelanomaActive, not recruitingNCT03313206Phase 2
• AZD5363 in Patients With Advanced Solid Tumors Harboring AKT MutationsCompletedNCT03310541Phase 1
• Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedNCT03308201Phase 1
• Bioavailability and Food Effect Study of Two Formulations of PF-06650833CompletedNCT03308110Phase 1
• Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive, not recruitingNCT03304080Phase 1/2
• A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell MalignancyCompletedNCT03301207Phase 1
• Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy SubjectsCompletedNCT03301181Phase 1
• Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid CancerStatus unknownNCT03300765Phase 2
• Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLCStatus unknownNCT03300115Phase 2
• Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1

← Protein Kinase Inhibitors overview